S&P 500   3,585.62
DOW   28,725.51
QQQ   267.26
EV Battery Maker Freyr Set For Major Global Expansion
Trade With Artificial Intelligence for Happiness (Ad)pixel
Want to Increase Your Conversion Rates? This Is the Biggest Threat to Your Success.
Russia accused of 'kidnapping' head of Ukraine nuclear plant
Reclusive trader scores 20 years of winning trades. Learn how. (Ad)pixel
How major US stock indexes fared Friday 9/30/2022
MarketBeat: Week in Review 9/26 – 9/30
Trade With Artificial Intelligence for Happiness (Ad)pixel
EU chief: New Greece-Bulgaria gas pipeline 'means freedom'
West rejects Putin's claim it sabotaged Baltic gas pipelines
S&P 500   3,585.62
DOW   28,725.51
QQQ   267.26
EV Battery Maker Freyr Set For Major Global Expansion
Trade With Artificial Intelligence for Happiness (Ad)pixel
Want to Increase Your Conversion Rates? This Is the Biggest Threat to Your Success.
Russia accused of 'kidnapping' head of Ukraine nuclear plant
Reclusive trader scores 20 years of winning trades. Learn how. (Ad)pixel
How major US stock indexes fared Friday 9/30/2022
MarketBeat: Week in Review 9/26 – 9/30
Trade With Artificial Intelligence for Happiness (Ad)pixel
EU chief: New Greece-Bulgaria gas pipeline 'means freedom'
West rejects Putin's claim it sabotaged Baltic gas pipelines
S&P 500   3,585.62
DOW   28,725.51
QQQ   267.26
EV Battery Maker Freyr Set For Major Global Expansion
Trade With Artificial Intelligence for Happiness (Ad)pixel
Want to Increase Your Conversion Rates? This Is the Biggest Threat to Your Success.
Russia accused of 'kidnapping' head of Ukraine nuclear plant
Reclusive trader scores 20 years of winning trades. Learn how. (Ad)pixel
How major US stock indexes fared Friday 9/30/2022
MarketBeat: Week in Review 9/26 – 9/30
Trade With Artificial Intelligence for Happiness (Ad)pixel
EU chief: New Greece-Bulgaria gas pipeline 'means freedom'
West rejects Putin's claim it sabotaged Baltic gas pipelines
S&P 500   3,585.62
DOW   28,725.51
QQQ   267.26
EV Battery Maker Freyr Set For Major Global Expansion
Trade With Artificial Intelligence for Happiness (Ad)pixel
Want to Increase Your Conversion Rates? This Is the Biggest Threat to Your Success.
Russia accused of 'kidnapping' head of Ukraine nuclear plant
Reclusive trader scores 20 years of winning trades. Learn how. (Ad)pixel
How major US stock indexes fared Friday 9/30/2022
MarketBeat: Week in Review 9/26 – 9/30
Trade With Artificial Intelligence for Happiness (Ad)pixel
EU chief: New Greece-Bulgaria gas pipeline 'means freedom'
West rejects Putin's claim it sabotaged Baltic gas pipelines
NASDAQ:EVGN

Evogene - EVGN Stock Forecast, Price & News

$0.83
-0.02 (-2.35%)
(As of 09/30/2022 12:00 AM ET)
Add
Compare
Today's Range
$0.81
$0.89
50-Day Range
$0.76
$1.29
52-Week Range
$0.68
$2.93
Volume
73,496 shs
Average Volume
53,540 shs
Market Capitalization
$34.19 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$6.00

Evogene MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
622.9% Upside
$6.00 Price Target
Short Interest
Healthy
0.55% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
1.38mentions of Evogene in the last 14 days
Based on 3 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($0.74) to ($0.47) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.50 out of 5 stars

Medical Sector

211th out of 1,093 stocks

Agricultural Chemicals Industry

3rd out of 10 stocks

EVGN stock logo

About Evogene (NASDAQ:EVGN) Stock

Evogene Ltd., together with its subsidiaries, operates as a computational biology company. It focuses on product discovery and development in multiple life-science based industries, including human health and agriculture, through the use of its Computational Predictive Biology (CPB) platform. The CPB platform, incorporating a deep understanding of biology leveraged through big data and artificial intelligence, designed to computationally discover and uniquely guide the development of life-science products based on microbes, small molecules, and genetic elements. The company operates through three segments: Agriculture, Human Health, and Industrial Applications. The Agriculture segment develops seed traits, ag-chemical products, and ag-biological products to enhance plant performance. Its products focus on various crops, such as corn, soybean, wheat, rice, and cotton. The Industrial Applications segment develops enhanced castor bean seeds to serve as a feedstock source for other industrial uses. The Human Health segment discovers and develops human microbiome-based therapeutics for the treatment of immuno-oncology, GI related disorders, and antimicrobial resistance organisms. The company also provides medical cannabis products. It operates in the United States, Israel, Brazil, and internationally. The company has strategic collaborations and licensing agreements with agricultural companies, such as BASF SE, Corteva, and Bayer; and through its subsidiary, Canonic Ltd., has a collaboration agreement with Cannbit Ltd. for the development of novel medical cannabis products. Evogene Ltd. was founded in 1999 and is headquartered in Rehovot, Israel.

Receive EVGN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Evogene and its competitors with MarketBeat's FREE daily newsletter.

EVGN Stock News Headlines

Lavie Bio Appoints Guri Oron As CEO - Nasdaq
Evogene Reports Second Quarter 2022 Financial Results
Evogene (EVGN) Reports Q2 Loss, Tops Revenue Estimates
Earnings Outlook For Evogene
See More Headlines
Receive EVGN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Evogene and its competitors with MarketBeat's FREE daily newsletter.

EVGN Company Calendar

Last Earnings
11/16/2021
Today
10/01/2022
Next Earnings (Estimated)
11/16/2022
Fiscal Year End
12/31/2022

Industry, Sector and Symbol

Industry
Agricultural chemicals
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:EVGN
Employees
133
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$6.00
High Stock Price Forecast
$8.00
Low Stock Price Forecast
$3.00
Forecasted Upside/Downside
+622.9%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
3 Analysts

Profitability

Net Income
$-27,790,000.00
Net Margins
-3,172.80%
Pretax Margin
-3,486.15%

Debt

Sales & Book Value

Annual Sales
$930,000.00
Book Value
$2.46 per share

Miscellaneous

Free Float
N/A
Market Cap
$34.19 million
Optionable
Not Optionable
Beta
1.23

Key Executives

  • Mr. Ofer Haviv CPA (Age 56)
    CEO & Pres
    Comp: $472k
  • Mr. Mark Kapel (Age 45)
    Chief Technology Officer
    Comp: $295k
  • Dr. Elran Hillel Haber M.B.A. (Age 42)
    Ph.D., Chief Exec. Officer of Biomica Ltd
    Comp: $287k
  • Mr. Yaron Eldad (Age 57)
    Chief Financial Officer
  • Dr. Eyal Emmanuel (Age 49)
    Chief Scientific Officer
  • Mr. Sassi Masliah (Age 43)
    Exec. VP of Corp. Devel.
  • Ms. Liat Foigel Wejgman
    VP of HR
  • Dr. Nir Arbel (Age 42)
    Chief Product Officer
  • Mr. Dotan Borenstein
    Chief Bus. Officer of Lavie Bio Ltd.
  • Mr. Eyal Ronen
    Exec. VP of Bus. Devel.













EVGN Stock - Frequently Asked Questions

Should I buy or sell Evogene stock right now?

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Evogene in the last year. There are currently 3 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" EVGN shares.
View EVGN analyst ratings
or view top-rated stocks.

What is Evogene's stock price forecast for 2022?

3 analysts have issued twelve-month price objectives for Evogene's shares. Their EVGN share price forecasts range from $3.00 to $8.00. On average, they anticipate the company's stock price to reach $6.00 in the next year. This suggests a possible upside of 622.9% from the stock's current price.
View analysts price targets for EVGN
or view top-rated stocks among Wall Street analysts.

How have EVGN shares performed in 2022?

Evogene's stock was trading at $1.64 on January 1st, 2022. Since then, EVGN stock has decreased by 49.4% and is now trading at $0.83.
View the best growth stocks for 2022 here
.

When is Evogene's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, November 16th 2022.
View our EVGN earnings forecast
.

How were Evogene's earnings last quarter?

Evogene Ltd. (NASDAQ:EVGN) posted its quarterly earnings data on Tuesday, November, 16th. The biotechnology company reported ($0.19) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.17) by $0.02. The biotechnology company had revenue of $0.15 million for the quarter, compared to analyst estimates of $0.14 million. Evogene had a negative net margin of 3,172.80% and a negative trailing twelve-month return on equity of 54.76%. During the same quarter last year, the business earned ($0.17) earnings per share.

What other stocks do shareholders of Evogene own?
What is Evogene's stock symbol?

Evogene trades on the NASDAQ under the ticker symbol "EVGN."

How do I buy shares of Evogene?

Shares of EVGN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Evogene's stock price today?

One share of EVGN stock can currently be purchased for approximately $0.83.

How much money does Evogene make?

Evogene (NASDAQ:EVGN) has a market capitalization of $34.19 million and generates $930,000.00 in revenue each year. The biotechnology company earns $-27,790,000.00 in net income (profit) each year or ($0.78) on an earnings per share basis.

How many employees does Evogene have?

The company employs 133 workers across the globe.

How can I contact Evogene?

Evogene's mailing address is 13 GAD FEINSTEIN STREET PARK REHOVOT P.O.B 2100, REHOVOT L3, 76121. The official website for the company is www.evogene.com. The biotechnology company can be reached via phone at (728) 931-1900, via email at ir@evogene.com, or via fax at 972-8946-6724.

This page (NASDAQ:EVGN) was last updated on 10/1/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Privacy Policy | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart's disclaimer.